2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 217-219
Treatment Considerations, Combination Therapy, Adverse Events, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Platelet Disorders, Thrombocytopenias, Immunology, Autoimmune Disorders, Research, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric
PAPER

26 Major bleeding in adults with immune thrombocytopenia: Characteristics, recurrence, and predictors from the nationwide carmen-France registry

Lucas Khellaf, MD-PhD student, Marianne Lepetit2, Laurie Chabbert3, Laetitia Languille4, Yoann Zadro5, Serge Madaule6, Clément Gourguechon, MD7, Francis Gaches, MD8, Jean-Francois Viallard, MD, PhD9, Stephane Cheze, MD10, Gauthier Martin11, Sarah Khatibi12, Thomazeau Joséphine13, Marc Ruivard14, Sylvain Audia15, Louis Terriou16, Margaux Lemonnier17, Quitterie Reynaud18, Mikael Ebbo19, Miguel Carreiro, MD20, Thomas Moulinet21, Mathilde Roumier22, Delphine Gobert23, Aurélie Saunier24, Ailsa Robbins25, Natacha Brun26, Yann Leveneur27, Marie Guille28, Laurent Balardy29, Thibault Comont, MD30, Delphine Bonnet31, Marc Michel32, Bertrand Godeau33, Guillaume Moulis Sr, MD-PhD34, Matthieu Mahevas Sr, MD-PhD35
1 Henri Mondor University Hospital, Créteil, France
2 Toulouse University Hospital, Toulouse, France
3 Toulouse University Hospital, Toulouse, France
4 Henri Mondor University Hospital, Créteil, France
5 Toulouse University Hospital, Toulouse, France
6 Department of Internal Medicine, Albi Hospital, Albi, France., Albi, France
7 Department of Clinical Hematology and Cell Therapy, Amiens-Picardie University Hospital, Amiens, France., Amiens, France
8 Department of Internal Medicine, Auch en Gascogne Hospital, Auch, France, Auch, France
9 Department of Internal Medicine, Haut-Lévêque Hospital, Bordeaux University Hospital, Bordeaux, France., Bordeaux, France
10 Department of Hematology, Caen University Hospital, Caen, France., Caen, France
11 Department of Hematology, Jean Rougier Hospital, Cahors, France., Cahors, France
12 Department of Infectious Diseases, Castres-Mazamet Intercommunal Hospital, Castres, France., Castres, France
13 Department of Internal Medicine, Ariège Valleys Hospital, Saint-Jean-de-Verges, France., Saint-Jean-de-Verges, France
14 Department of Internal Medicine, Clermont-Ferrand University Hospital, Clermont-Ferrand, France., Clermont-Ferrand, France
15 Department of Internal Medicine and Clinical Immunology, Dijon Bourgogne University Hospital, Université Bourgogne Europe, Dijon, France., Dijon, France
16 Department of Internal Medicine and Clinical Immunology, Lille University Hospital, Lille, France., Lille, France
17 Department of Internal Medicine, Lourdes Hospital, Lourdes, France., Lourdes, France
18 Department of Internal Medicine, Lyon Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, France., Lyon, France
19 Department of Internal Medicine, La Timone Hospital, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University, Marseille, France., Marseille, France
20 Department of Hematology, Montauban Hospital, Montauban, France., Montauban, France
21 Department of Internal Medicine and Clinical Immunology, Nancy University Hospital, Vandœuvre-lès-Nancy, France; UMR 7365 CNRS-Université de Lorraine IMoPA, University of Lorraine, Vandœuvre-lès-Nancy, France., Nancy, France
22 Department of Internal Medicine, Foch Hospital, Suresnes, France, Suresnes, France
23 Department of Internal Medicine, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Paris, France., Paris, France
24 Department of Internal Medicine and Infectious Diseases, Périgueux Hospital, Périgueux, France., Périgueux, France
25 Department of Internal Medicine, Clinical Immunology and Infectious Diseases, Reims University Hospital, Reims, France., Reims, France
26 Department of Internal Medicine, Jacques Puel Hospital, Rodez, France., Rodez, France
27 Department of Internal Medicine, Bigorre Hospital, Tarbes, France., Tarbes, France
28 Department of Internal Medicine, Joseph Ducuing Hospital, Toulouse, France., Toulouse, France
29 Department of Geriatric Medicine, Gérontopôle, Toulouse University Hospital, Toulouse, France., Toulouse, France
30 Department of Internal Medicine, Toulouse Cancer University Institute (IUCT-Oncopole), Toulouse University Hospital, Toulouse, France., Toulouse, France
31 Department of Internal Medicine, Rangueil Hospital, Toulouse University Hospital, Toulouse, France., Toulouse, France
32 Henri Mondor University Hospital, Créteil, France
33 Henri Mondor University Hospital, Créteil, France
34 Toulouse University Hospital, Toulouse, France
35 Henri Mondor University Hospital, Créteil, France
Background

Major bleeding is the most feared complication of immune thrombocytopenia (ITP), but the profile of patients at highest risk and the likelihood of recurrence after an initial event remain poorly defined. We aimed to characterize adults with ITP experiencing major bleeding and to identify baseline predictors of recurrent major bleeding during follow-up.

Methods

We analyzed the CARMEN-France registry (NCT02877706), a prospective, multicenter cohort enrolling incident patients with newly diagnosed ITP (platelet count <100 ×10?/L) across 50 French centers. Adults included through December 31, 2022 were studied; data were extracted in April 2024. Major bleeding was defined as mouth hemorrhagic bullae, gross hematuria, gastrointestinal bleeding, or intracranial hemorrhage at ITP onset and/or during follow-up. Initial characteristics of patients with major bleeding were compared with ITP patients without major bleeding. Among patients with major bleeding at diagnosis, baseline factors associated with a new major bleeding during follow-up were assessed by uni- and multivariable logistic regression (odds ratios [OR], 95% CI); treatment-related variables measured during follow-up were not considered predictors, being a posteriori exposure. Analyses were performed using R software (4.6.1).

Results

Of 2,111 adults with primary and secondary ITP, 234 (11.1%) experienced major bleeding as previously defined, including hemorrhagic bullae (75.6%), gross hematuria (26.5%), gastrointestinal bleeding (17.1%), and intracranial hemorrhage (14.5%; namely 1.6% of the whole cohort). Compared with the 1,877 patients without major bleeding, these 234 patients were significantly older (median age 78 vs 58 years, p<0.001), more often males (62% vs 45%, p<0.001), had lower platelet counts at diagnosis (median 5 vs 18 ×10?/L, p<0.001), more comorbidities (Charlson score ≥1, 47.4% vs 27.1%, p<0.001), and were more frequently receiving antithrombotic medication (41.0% vs 16.2%, p<0.001), including anticoagulant monotherapy (18.4% vs 5.4%), antiplatelet monotherapy (19.7% vs 9.9%), or combination therapy (3.0% vs 1.0%). Non-major bleeding (e.g., cutaneous or mucosal bleeding not meeting major bleeding criteria) at diagnosis was also more frequent among patients with major bleeding than among those without (46.2% vs 23.1% of patients in the respective group, p<0.001). Of note, the rate of secondary ITP was similar between groups (17.5% vs 18.5%; p=0.7).

Among the 234 patients with major bleeding, after a median follow-up of 15.5 months (Q1–Q3, 5.3–34.6), 187 (80%) experienced their first event at ITP diagnosis whereas 47 (20%) experienced their first event during follow-up. Of note, these 47 patients represented only 2.4% of the 1,924 patients without major bleeding at diagnosis. Of the 187 patients with a first major bleeding event at diagnosis, 38 (20.3%) experienced at least one recurrent major bleeding event during follow-up (median 82.5 days [24–232]). Among all patients with major bleeding during follow-up (whether as a first or recurrent event), the median number of major bleeding episodes was 2 (Q1–Q3, 1–2; maximum, 7). Intracranial hemorrhage occurred in 23 of the 187 patients bleeding at diagnosis (12.3%) and 16 of the 85 patients bleeding during follow-up (18.8%), including 5 patients at both time points. 39 patients died during follow-up, including 7 deaths (18%) directly related to major bleeding, including intracranial and gastrointestinal hemorrhage.

Among patients with major bleeding at diagnosis, secondary ITP was the only baseline factor independently associated with a new major bleeding during follow-up (adjusted OR 3.16; 95% CI 1.06–9.20; p=0.035), whereas age ≥80 years was no longer significant after adjustment (OR 1.72; 95% CI 0.71–4.23; p=0.23).

Conclusions In this large nationwide cohort of adults with ITP, major bleeding occurred in 11% of the patients, mostly at disease onset (80%) and predominantly in elderly males on antithrombotic treatment. Conversely, the risk of a first major bleeding event during follow-up was low (2.4%) among patients without major bleeding at diagnosis. One in five patients with major bleeding at diagnosis experienced recurrence, secondary ITP being the only independent factor of recurrence.
Lucas Khellaf, MD-PhD student: No relevant conflicts of interest to declare.